Merck’s 11% Drop: A Few Quick Points 2-4-25

In this episode, Scott Becker breaks down Merck’s 11% stock decline, discussing its strong 2024 performance, concerns over slower growth in 2025, a weak drug pipeline, and upcoming patent expirations.

Podcast: Play in new window | Download